Small Intestinal NET clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Surufatinib in European Patients With NET
Sorry, in progress, not accepting new patients
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
Orange, California and other locations

Last updated: February 8, 2024